Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Peregrine Pharmaceuticals (PPHM)

Add PPHM Price Alert      Hide Sticky   Hide Intro
Moderator: TekNuLoof, cjgaddy, keep_trying, north40000, biopharm, 4OurRetirement
Search This Board: 
Last Post: 12/15/2017 2:25:11 AM - Followers: 847 - Board type: Free - Posts Today: 2

Peregrine Pharmaceuticals, Inc. (PPHM), Tustin CA. is committed to improving the lives of patients by delivering high quality pharmaceutical products through its contract development & mfg. organization (CDMO) services and through advancing and licensing its investigational immunotherapy and related products. Peregrine's in-house CDMO services, including cGMP mfg. & dev. capabilities, are provided through its wholly-owned subsidiary Avid Bioservices, Inc. ( ), which provides development & biomfg. services for both Peregrine & 3rd-party customers. The company is also working to evaluate its lead immunotherapy candidate, BAVITUXIMAB, in combination with immune stimulating therapies for the treatment of various cancers, and developing its PROPRIETARY EXOSOME TECHNOLOGY for the detection & monitoring of cancer using assays that are able to detect small amts of PS+ Exosomes in a patient's blood sample.
Bavituximab, a phosphatidylserine(PS)-targeting antibody, represents a new approach to treating cancer (3:34 video). Bavituximab was invented by UTSW's Dr. Philip Thorpe (1951-2013), and research continues in Dr. Rolf Brekken's UTSW lab.

DEC. 2017 Company Update - "Transitioning to a Pure-Play CDMO, Avid Bioservices, Inc."
12-11-17 10-Q for q/e 10-31-17:
Business Description – We are a company committed to improving the lives of patients by manufacturing pharmaceutical products through our CDMO, Avid Bioservices, Inc.
"Over the next 60 days, we plan to complete the transition from a R&D company to a dedicated CDMO company focused on dev. & mfg. of biopharmaceutical products derived from mammalian cell culture.
We plan to take ADDL. STEPS steps over the near term, including but not limited to:
1. Rebranding the company as Avid Bioservices, Inc.
2. Changing our ticker symbol on the NASDAQ Capital Market to align with our rebranding efforts
3. Broadening our sales force
4. Increasing our marketing efforts to support our rebranding & vision
5. Completing the wind down of all R&D activities and the potential licensing/divestiture of our assets related to our R&D operations.”

BAVI MOA: By blocking the immunosuppressive signal of exposed PS, Bavi mediates multiple immunostimulatory changes in the tumor environment, including a reduction of tumor-promoting immune cells and an increase in tumor fighting (M1) macrophages, dendritic cells, and cytotoxic T-cells (CD8+ CD45+ CD3+) that fight solid tumors. (see: AACR'15 & ASCO'15 & ImVacS’15 & SITC'15 & S.King/1-18-16 & AACR'16 & AACR'17 & ASCO'17)
COLLABS: In addition to the ongoing UTSW/Brekken/Schroit research collab., Peregrine began working w/Mem-Sloan-Kettering(Jedd Wolchok Lab) in Jul'15(2 known studies a/o 4-2017: #1/Bavi+PD1+Rad, #2/Bavi+”ACT) to investigate “Novel PS-Targeting Immunotherapy Combos”, then w/AstraZeneca in Aug'15(see PR) to run human trials evaluating Bavi+Durvalumab(Imfinzi) in "mult-solid-tumor-types", and w/The Natl. Comprehensive Cancer Network (NCCN) in Jan'16 via a $2M res. grant to NCCN which will “significantly expand Peregrine's clinical evaluation of bavituximab” at “27 of the world's leading cancer centers” (9-16-16: NCCN selects 3 Bavi Trials to in 2017 at Moffitt/MassGen/JohnsHopkins). Also, w/Duke Univ. (See Dr. Herbert K. Lyerly: AACR-IO/10-22-16), MD Anderson (See Dr. Jason Fleming),  Rutgers Univ. (See Dr. Raymond Birge), and ImmunoVaccine Inc. (AACR'17 4-4-17 #3657). MORE on PreClin. Collabs:
AVID: Peregrine also operates Avid Bioservices, a wholly owned cGMP CMO subsidiary, which provides contract mfg. services on a fee-for-service basis (revs. May'06-Oct17=$271.1mm), as well as support of Peregrine's own product pipeline.
5-2017: Avid II(Myford) expands; total Avid mfg. capacity now > 11,000L - see

4-2-13: Peregrine Mourns Loss of Dr. Philip E. Thorpe (1951-2013)  
"Phil will be sorely missed as a colleague and friend. At Peregrine, each of us is pursuing Phil's dream of bringing important drugs to patients who need them based on his basic research. We are more motivated than ever to see this dream through."
…Dr. Thorpe’s successor at UTSW: long-time colleague, co-inventor of 2C3, Dr. Rolf A. Brekken, PhD -

8-2014: UK colleagues from Chester Beatty Labs(ICR/Univ-London), ICRF(IsraelCancerRes), & UTSW create memorial for Dr.Thorpe in London’s Chelsea Physic Garden:

Yahoo Quote & Profile for PPHM: ...Nasdaq Quote: ...PPHM Tweets:
IR: Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401, Tim Brons (Media) 415-675-7402
• PPHM's 7-13-17 Ronin PR had: MEDIA CONTACTS - John Christiansen / Matt Reid, Sard Verbinnen & Co., 415-618-8750 / 310-201-2040


Dec11: FY'18Q2 (qe 10-31-17) Financials & Conf. Call - PR & CC Transcript:
Jan18: Peregrine's 2017 Annual Shareholder’s Mtg – 11-13-17/PR: VotingRecDate=11-27-17
…10am at Avid’s Myford Facility, 14191 Myford Road, Tustin, CA 72780
...PROXY/14A: =>Vote here:

SCIENCE: "Evolution has favored pathogenesis that resembles apoptosis."
Dr. Judah Folkman: ”This [Thorpe’s VTA research] is very promising and very elegant work... The whole goal is really 2-part, reducing the harsh side effects of cancer treatment, and reducing the chance that some cancer cells will evade treatment. That would be a big step in the next decade, and anti-vascular therapy will play a major role." (’97 & ’02 &
Bavituximab MOA & Clinical Data:
...Bavi Publications:
...Bavi Posters & Presentations:
Bavi MOA: Video (3:34) added ~3-2014 "Bavituximab: A Novel Immunotherapy Candidate Targeting an Upstream Immune Checkpoint to Fight Cancer"
Bavi MOA: Video (1:33) on Bavi’s Immunotherapeutic MOA added to Youtube on 3-27-14

Expert Quotes/Commentary On Bavituximab's Moa/Potential:
Peregrine's Patent Estate - excl. licenses from UTSW MDA U-CALIF USC:
7-16-12 Form 10-K (fy/e 4-30-12): License Agreements between PPHM & UTSW/DNA/Avanir/Lonza (pg.10)
…Royalty %'s payable to UTSW/Dallas on sales of future-approved Anti-PS drugs will be in the "low single digits"
4-2006: Tarvacin (chimeric 3G4) will henceforth be referred to by its generic name, BAVITUXIMAB, to avoid confusion with OSI's anti-cancer drug Tarceva.
BAVI MOA 4-3-17 AACR'17: Joint Memorial Sloan Kettering (Wolchok Lab) & PPHM poster: “PS Targeting+Adoptive TCell Transfer (ACT) Eliminates Adv. Tumors w/o Off-Target Toxicities, Melanoma”
BAVI MOA 1-30-17 Mol.Cancer article: MDA/J.Fleming, UTSW/Brekken, “PreClin. Eval of DNAtrix's DNX2401+BAVI for Pancreatic Cancer”
...Combo DNAtrix's DNX-2401(Oncolytic Virus) + BAVI “significantly inhibited tumor growth; further enhanced its anticancer activity; warrants further clinical evaluation...”
BAVI MOA 11-14-16 SITC’16: Joint Memorial Sloan Kettering (Wolchok Lab) & PPHM poster on Triple Combo Rad+Bavi+aPD1 vs. Melanoma
...Dr. Jedd Wolchok states, “Based on these study results, we believe that the targeting of PS is having meaningful activity within the tumor microenvironment in the B16 melanoma model. It appears that this activity creates a more immune active environment in which other treatments, including radiation, are able to have a greater anti-tumor impact." => AACR'17 Update 4-2-17 (#574)

BAVI MOA 10-22-16: Duke’s Herbert K. Lyerly (w/PPHM) poster on AntiPS/TNBC data at AACR’s Tumor Immunotherapy Conf./Boston
...”Modulating The Tumor Microenvironment to Enhance Cancer Immunotherapy by Inducing Phosphatidylserine Expression on the Tumor Surface”
BAVI MOA 9-27-16 AACR-CRI/Dr. Michael Gray: Preclin. Triple-Combo Bavi+PD1+LAG3 TNBC data in TNBC (80% Compl. Regression, Stat-Sig. Incr. in Key Tumor Fighting Immune Cells)
BAVI MOA 7-27-16 Shaul/Brekken/Thorpe/etal PLOS ONE article: Fhu/Bavi vs. APS-related Pregnancy Complications & Thrombosis
...”The potential clinical impact of 1N11 (Fhu Bavi) in patients with APS is substantial. Spring-boarding from the present discovery of 1N11 as a highly-effective, mechanism-based treatment for APS in a comprehensive series of mouse models of APS-related disorders, clinical studies of 1N11 now warrant consideration.”
BAVI MOA 5-11-16 Breast Cancer Res. article, B.Freimark/M.Gray/CW.Hughes-et-al, “PS-Targeting/Bavi Combo w/Anti-PD1/PDL1 in Triple.Neg-MBC”
...”our observations demonstrate that including PS-targeting antibodies such as bavituximab can enhance the anti-tumor activity of anti-PD-1/PD-L1 treatments, not only by increasing TIL responses but also by inhibiting cytokines stimulated by single-agent anti-PD-1 therapy that serve to suppress the immune response & promote tumor progression.”
BAVI MOA 4-20-16/AACR'16 & 4-4-16/Cancer-Immunology-Res.(AACR) article - preclin. data: Bavi combo w/anti-PD-1/anti-CTLA-4 “induces a shift in tumor microenvironment from immunosuppressive to immune active”
BAVI MOA 1-18-16: CEO Steve King explains PPHM's direct PS-Targeting advantage vs. the “individual-receptors” PS-binding approach of others like: Axl Mer TIM-3 RAGE Tyro3 GAS6 CD300a BAI1 MFG-E8 etc.
2-2016: Rutgers' Dr. Raymond Birge's relationship with Peregrine & UTSW's Dr. Rolf Brekken and his 2-26-16 article, “Phosphatidylserine is a Global Immunosuppressive Signal in Efferocytosis, Infectious Disease, and Cancer” and 9-26-16 AACR/CRI, “Characterization of a PS, TAM Receptor (Tyro3, Axl, Mertk), PDL1 Axis in Breast Cancer”

11-9-15 SITC'15: New Bavi+Checkpoint Inhibitors preclin. data (DUKE's Herbert K. Lyerly + PPHM + UTSW)
...Also, collab. with Dr. Bernard Fox (Immunotherapist/Earle A. Chiles Res.Inst.) on new Immuno-Profiling Clinical Test (Opal 6-plex quantitative IF Assay), PPHM roundtable with Raymond Birge (Rutgers), Douglas Graham (Emory), Dmitry Gabrilovich (Wistar), Rolf Brekken (UTSW), Maria Karasarides (AstraZeneca) - ”Combining Bavi w/anti-PD-1 significantly enhanced O/S… significant incr. CD45+, CD8+ and CD3+ T-cells… led a prolonged anti-tumor immune response which protected the animals against a re-challenge w/same tumor.”
BAVI MOA 8-26-15: Jeff Hutchins(VP/PreClin-Res) ImVacS’15 Talk – 29pg. Slideshow
…“Expansion & Activation of T Cells via the Targeting of the Immunosuppressive Ligand PS: Combination Strategy with Conventional, Targeted, and Checkpoint Inhibitor Therapy”
5-31-15: ASCO’15 Roundtable (webcast), “Raising the Immuno-Oncology Bar” - 7 panel members, incl. 3 Sloan Kettering researchers
BAVI MOA 3-25-15: PPHM/VP Dr. Jeff Hutchins’ presentation at "Immune Checkpoint Inhibitors Conf.", Boston - PDF(34 Slides):
BAVI MOA 2-9-15: PPHM's Dr. Bruce Freimark’s presentation at KEYSTONE "Tumor Immunology Meeting", Banff/CN – PR & Slides:
- - - -Peregrine's Anti-PS Mabs:
• PGN635 (B2GPI-dep.) is Fully-Human Bavituximab=1N11=AT004 (B2GPI-depen.); Genentech studying 89Zr-PGN635 as a Tumor Imaging Agent, “indep. of cancer type”
• PGN632 (B2GPI-indep.) is the Duke-PPHM-HIV candidate=11.31=AT005; also being studied by PPHM+LSU vs. Ocular Herpes (Acute HSV-1 Keratitis), see
• PGN650 is a human F(ab’)2 fragment that targets PS expression (1st ref’d in AACR’12 #2452) – see . 124I-PGN650 is Peregrine’s PS-Imaging candidate (see )
BETABODIES (Clipped/Nicked B2GPI - ex: KL15, “2nd-gen. PS-Targeting”) - bind to PS directly, are smaller in size (100 vs. 250KDa) and have a longer serum half-life (~5days) than natural antibodies (Bavi=~1day) – see
...6-22-17: Nature(BJC): AntiPS Exosomes in Breast & Pancreatic, Alan Schroit/Rolf Brekken etal (UTSW/PPHM SAB) - Betabody KL15C being tested.
…2/17/15: UTSW/PPHM’s BetaBodies patent#8,956,616 Awarded(Granted)

Examples of anti-PD-1 drugs in development: (PD1=”Programmed Cell Death Protein 1”)
1. Merck’s Keytruda(pembrolizumab=MK-3475, formerly=labrolizumab) <=’14/Melanoma, ‘15/NSCLC, ‘16/Head&Neck
2. BMS’s Opdivo(nivolumab) <=’14/Melanoma, ’15/NSCLC & RenalCell
3. AZN/MedImmune’s MEDI0680 (formerly=AMP514)
4. GSK’s AMP-224 (collab. with Amplimmune)
Examples of anti-PD-L1 drugs in development: (PD-L1=”PD1 ligand”)
1. BMS’s BMS-936559 (MDX-1105)
2.. Roche/DNA’s Tecentriq(atezolizumab, aka MPDL3280A) <=2016/Bladder & 2L/NSCLC
3. AZN/MedImmune’s Imfinzi(durvalumab=MEDI4736)<=2015 PPHM+AZN collab. & expansion to run trials in Lung & "mult. tumor types"
4. Pfizer/Merck-KgaA’s Avelumab (formerly MSB0010718C)
7-14-14/CC: Steve Worsley (VP/BusDev) said that Peregrine is “seeking collaborators that build on other checkpoints of pathways such as PD-1, IDO, immune-stimulatory drugs, and even vaccines…”
...Interesting: PPHM KOL/SRB’r Dr. Scott Antonia’s (Moffitt-CC/Tampa) role in IDO dev: <=“1st to report in 2002 that IDO inhibitors delay growth of human lung cancer cells”
Incyte’s immune checkpoint inhibitor INCB24360 is an oral inhibitor of IDO1 (indoleamine dioxygenase-1) –
NewLink Genetics’ immune checkpoint inhibitor indoximod is an oral inhibitor of IDO (indoleamine 2,3-dioxygenase) –
...“IDO pathway inhibitors are another class of immune check point inhibitors akin to the recently developed antibodies targeting CTLA-4 & PD-1 that represent potential breakthrough approaches to cancer therapy.”

"As of 4-30-17, we employed 319 full-time emps & 4 part-time emps." ('11=154/2, '12=172/2 '13=182/4 '14=180/4 '15=211/4 '16=281/3)
8-9-17: PPHM commenced a restructuring plan… expected to be completed in Oct’17… reduced workforce by 60 emps (20%), reduced R&D from 22 to 11.
...On 3-18-09, CFO P.Lytle (Cowen/Boston) stated, "We have 135 emps, 85 under Avid Bioservices, and the remaining 50 emps reside at the Peregrine corp. level - 35 in R&D & 15 in G&A."
In 10-2009, Dr. Robert Garnick joined Peregrine as Head/Regulatory ( ).  In his 24 years at Genentech (1984-2008; from Feb'01-Oct'08 as Senior V.P. of Regulatory, Quality & Compliance), he was responsible for 17 new product approvals, including most of DNA's top selling monoclonal antibody therapeutics such as Rituxan, Herceptin, Avastin, and Lucentis.  He was responsible for all the regulated aspects of Genentech's business, including drug development, commercial production, and promotional & labeling compliance.  As CEO Steve King said 6-29-11, "Rob is the ringmaster."
• See this 6-29-11 Minyanville article, "Peregrine Pharma's Secret Weapon"
• Examples of Dr. Garnick's work at Genentech on Avastin (bevacizumab) approvals:  
• All of Dr. Robert Garnick's public comments (thru 3-7-2014) while at Peregrine:

Latest 10K 4-30-17 iss. 7-14-17 PR: (Cash 4-30-17=$46.8mm); Amended 8-25-17:
Latest 10Q 10-31-17 iss. 12-11-17 PR: (Cash 10-31-17=$27.7mm)
ALL SEC filings for PPHM:
PPHM's Corp. Bylaws (a/o 11-14-14):
Poison Pill adopted 3-16-06: - 44-pg SEC filing: BUNGLER explains in plain language:
5-15-17: Parties Settle 2013 Shareholder Derivative CA Lawsuit vs. BOD(re: Fiduciary Duties)
...7-27-17: Final Settlement Hearing - transcript excerpts, comments by Judge J. Travis Laster:
10-13-16 2016 ASM Voting Results:
1-18-18 2017 ASM Voting Results:
Shares O/S as of 12-6-17=45,212,760 - history since 4-2006:
...A/O 10-31-17: 39,040 warrants o/s with wgt.avg. exercise price of $17.29 -- 4,123,054 stock options outstanding at a wgt.avg. exercise price of $8.96. (pg.14 10Q)
PPHM shares were 1:7 Reverse Split eff. 7-10-17 (315mm/$.606=>45mm/$4.24)
**NOTE: PPHM shares were 1:5 Reverse Split eff. 10-19-09 (~237mm/$.64=>~47.4mm/$3.20)
...4-12-17/8K: Nasdaq Delisting Notice($1 min.), 4-10-17 deadline missed; Peregrine to Appeal for Extension
...6-7-17/8K: Hearing Panel Grants Extension until 7-21-17 (must be over $1 by 7-7-17)

12-27-13: S-3 Registration, “up to $100,000,000”, Common & Preferred - S-3 cover: Michael A. Hedge (Leader, Life Sciences M&A team), K&L Gates LLP
...2-5-14: PPHM Announces Public Offering of 10.5% Series E Convertible Preferred Stock
...2-11-14: PPHM Raises net $16.2mm selling 700k Preferred Shares with 10.5% div. at $25/sh, convertible to common at $3/sh (8-K)
...6/14/14-7/14/13: PPHM Raises net $9.5mm selling 400k Preferred Shares with 10.5% div. at $25/sh, convertible to common at $3/sh (4-30-14 10-K pg. F-34; $20mm gross remaining)
...6-30-14: SABBY MGT. (led by Hal Mintz) holds 291600/PPHMP a/o 6-30-14 ($7.0mm@1.66/sh. common):
...4-13-14: PPHM Registers $30mm of 10.50% Series E Convertible Preferred Stock and $25mm ATM Common Stock in 2 424B5’s: &
...12-23-14: S-3 Registration, “up to $150,000,000”, Common & Preferred

A-T-M (At-The-Market) Sales 3/2009 - 7/14/17 ($272,500,000gr./34,869,747sh=$7.81/sh):

...12-29-10: ATM Agreement (up to $75mm) with MLV filed - 8K:
...3-9-12: PPHM files shelf to sell up to $150mm common stock, warrants, S3:
...12-28-12: New ATM Agreement (up to $75mm) with MLV filed - 424B5:
…6-13-14: New ATM Agreement (up to $25mm) with MLV filed - 424B5:
…8-7-15: New ATM Agreement (up to $20mm) with NOBLE filed - 424B5:
…8-7-15: New ATM Agreement (up to $30mm) with MLV filed - 424B5:
...7-14-17: ALL Existing ATM's are fully exhausted - cannot do anymore until a new one is opened (and reported via 424B5), against the $67mm remaining on the orig. $150mm shelf filed 4-23-14/S-3.
INSIDER-Trans: &
Inst. Holdings ( - updated qtly, 45-days after each q/e cutoff:
Short Interest, upd. twice a month: ...Updates 1 day earlier:
Director Eric Swartz's Jan-Feb'10 Buying Streak, 100k@$3.12preR/S = 14.3k@$21.84/sh:
9-8-11: Roth arranges direct sale of 893,179sh.@$7.77 to 3 inst's, net=$6.5mm

11-15-17/13D: Group Ronin Trading/SWInvest (John Stafford III+Roger Farley+Stephen White) now owns 9.6% stake (4,325,889sh.) in PPHM
FULL HISTORY of PPHM-Ronin PR’s, Letters, 13-D’s, Form4’s, Proxy’s, etc:
...4,173,391 COMMON - 9.2% of 45,212,760 common O/S at 12-6-17 (total beneficial=4,325,889 if Pref. conv. x1.1905 to Common)
...128,099 PREFERRED – 7.8% of 1,647,760 preferred O/S at 11-27-17

......As a Group, ie, “people that share the furtherance of a common objective/concerted action”; 13D’s are reserved for ACTIVE INVESTORS who may be “interested in agitating for some kind of a change at the company”.
...11-28-17: PPHM+RONIN Settle - Reconstituted 7-Member BOD (Johnson/Swartz/Pohl/King resign)
......Full Agreement(8-K): Header: Complete Agreement: PROXY/12-7-17:
......Profiles of all 7 BOD members & Compensation as of 11-28-17:
.......(Joseph Carleone/Chair, Richard Hancock, Gregory Sargen, Joel McComb, Roger Lias, Mark Bamforth, Patrick Walsh)

...10-30-17: RONIN/SW-Invest issues 30-pg. PDF Presentation, “Shareholders Seeking Change”
...10-10-17: RONIN/SW-Invest PR adding 4th BOD Nominee (James Egan) and ups stakes 8.8%=>8.9%

...8-29-17: RONIN/SW-Invest PRELIM. Proxy Statement (14A) - includes 35-pt. chronology of events (1-17-17 thru 8-14-17) & all Ronin/SW PPHM stock trans.
...8-14-17: Ronin/SW-Invest PR commenting on PPHM's 8-11-17 PR (laying off 20% employees)
...7-20-17: Ronin/SW-Invest Letter to Employees of Peregrine; PPHM Comments
...7-13-17: Ronin/SW-Invest Letter to Stockholders; PPHM Comments - Ronin nominates Gregory Sargen, Brian Scanlan, Saiid Zarrabian for election to PPHM's board at next ASM ~10-12-17.

10-30-15: Kenneth Dart (Eastern Capital) acquires 9.5% stake (4,300,992sh.) in PPHM
...3,777,183 COMMON - 8.4% of 45,212,760 common O/S at 12-6-17 (total beneficial=4,300,992 if Pref. conv. x1.19 to Common, 9.6%)
...440,000 PREFERRED - 26.7% of 1,647,760 preferred O/S at 11-27-17
...…...9-29-17/Form4: <=No chg. in Ownership; has had <10% stake for many months due to dilution. ??

Plus, INSTITUTIONS a/o 9-30-17 (+ 11-13-17 Tappan/13G): 9,536,290sh. = 21.1% (of 45,212,760)
...TOTAL Large Shareholders: Ronin(4,325,889) + EastCap/Dart(4,300,992) + INST(9,536,290) = 18,163,171shs., 40.2% of 45,212,760 O/S at 12-6-17.
Tappan Street (Prasad Phatak) 3,915,611 +2,259,359 <=per 11-13-17/13G
Vanguard Group                1,518,110   +488,355
Blackrock (Larry Fink)          761,302    -44,720
Bandera Partners                555,000   +351,996
Renaissance Technologies        547,190    +66,030
Geode Capital Mgt.              225,676         -3
Fondren Mgt.                    205,000        NEW
Stifel Financial                204,305   +200,762
Eqis Capital Mgt.               143,595     -6,804
Wells Fargo & Co.               117,829    +69,488
Connor Clark & Lunn              98,772        NEW
Brown Advisory Sec.              82,858         -1
Pdt Partners                     82,800        NEW
And this big Q3 drop:
#18 Kennedy Capital Mgt.         69,820 -1,324,246

8-6-10: Bavituximab listed #8 in EP-Vantage's 'Biggest Unpartnered Pipeline Assets' chart, with NPV=$1.022b:
5-22-13: Citigroup analyst Andrew S. Baum’s report, "Immunotherapy - The Beginning of the End for Cancer"
…”A new wave of medicines that tap the power of the immune system to fight cancer could become the biggest drug class in history… We believe this market will gen. sales of up to $35B/yr. over the next 10yrs and be used in some way in the mgt. of up to 60% of all cancers…”
Noble Financial/Kumaraguru Raja (init. 7-16-15); 9-29-16: Buy/PT=$10.00
FBR & Co./ThomasYip 9-9-16: Outperform/PT=$1.00
Roth Capital /Joe Pantginis (init. 7-15-10), 7-15-16: Neutral/$.50 <="In Transition" a/o 12-2016
MLV/George B. Zavoico(Jones Trading?) - init. 2-8-10 Buy/PT=$10, CURR: Buy/$3.50 <=dropped 2015
Piper Jaffray/Charles Duncan - init. 3-5-13 <=Coverage dropped 12-2015
JMP Securities/Jason Butler - init. 8-30-2011 OutPerf/PT=$5, CURR: OutPerf/$6.50 <=7-2014: dropped from
LifeTech-Cap/Steve Dunn - init. 4-14-10 Spec-Buy/PT=$8, CURR: Spec-Buy/$5 <=Dropped 4-2012
1-2011: PPHM has Exec. Info. Report (EIO) prepared by Crystal Research (Jeffery Kraws):
12-21-07/Terminated: Rodman&Ren. (Jaikaria/Benjamin) initiate: Mkt-Perform:

AVID BIOSERVICES, Inc. (Peregrine's Mfg. Subsidiary):
12-11-17: PPHM's Revs & Burns By Qtr Table, FY07/Q1 thru FY18/Q2 (q/e 10-31-17): (since 5-2006: Avid=$271.1mm, Total=$297.7mm, incl.Govt)
......Avid FY18 (fye 4-30-18) revs guidance: $50-55mm; committed backlog=$33mm.
11-29-17: Tracy L. Kinjerski (ex-CMC Biologics) joins Avid as VP/Bus.Operations
9-11-17: Roger J. Lias (ex-Allergan) to become Avid’s President and join PPHM’s BOD eff. 9-25-17
7-14-17: Avid Scientists develop “Antibody Discovery & Characterization Platform (TM: EnAbl)”
...S.King: “through which we can generate antibodies against virtually any target. These capabilities are state-of-the-art and meant for rapid screening for high affinity antibodies as drug candidates.”

5-2017: Avid II (Myford) adds 2 MilliporeSigma Mobius 2,000L single-use bioreactors; total mfg. capacity now ">11,000L".
5-10-17: Halozyme comments on Avid II(Myford) expansion in their 3-31-17/10Q pub. 5-9-17:
..."validation of the new facility is scheduled to end in Q2/2017… Once this new facility is approved, it will become the primary source for Roche of bulk rHuPH20.”
2-28-17: Avid & Cook remain Halozyme's 2 CMO's (“working to scale-up/validate/qualify Avid II/Myford for Roche collab.”):
...9-19-2017: Catalent to acquire CDMO Cook Pharmica for $950M ($179M/sales x 5.3)
6-2-16: Corp.Update – Avid Expansion & Drug Development -
5-23-16: Pete Gagnon (100pubs/presentations, 12+patents, 30 pending patents) Appointed VP/Process-Services of Avid – See Oct'15:
3-7-16/Avid II: Formal Commissioning of Avid's New 40,000sq "Myford" Facility, “single-use/fully disposable” (potentially $40M addl revs)
12-10-15/Avid II: Avid Expansion into MYFORD Facility now GMP-run ready (potential +$40mm sales) - contemplating further expansion
6-17-15: Avid’s John Haney (ex-Genentech/Pfizer) speaking at BIO-INTL’5/Philly &
...”Designing & Implementing Avid’s New State-of-the-Art Single-Use Facility for Late Ph.3 & Commercial Prod.” - SK: "We've seen tremendous interest for production in the new facility, both from new & existing clients"
12-10-14: Avid to Double Mfg. Capacity (“expanding client roster; potential commercial launch of bavituximab”) &

3-24-15: Avid Receives CMO Leadership Awards for Its Commitment to Innovation & Reliability
3-12-13: Avid Q3'FY13 GP=$3.3mm; S.King 3-2012, "We have a profitable CMO, Avid Bioservices"
2-26-13: Avid Presents QbD/CPPs/CQAs at "BiopharmDev/Prod-Week"
4-2-12 AACR'12: Avid presents New Mab-Eng. Process (Fc/ADCC), Client Proj. (see #2510)
6-14-10: Avid adds 'Line #4 FILL-FINISH' capability,
5-3-10: PPHM leases addl. 11,000sq adjacent space (Avid exp?):
9-21-09: Avid becomes sole U.S. W.Coast CMO in Boehringer Ingelheim's Global Prod. Alliance Network
11-10-08: Avid expands capacity by adding 100L & 1000L Hyclone bioreactors:
6-25-08: Avid Selected as 1st U.S. CMO for DSM/Crucell's PER.C6 Cell Line:
7-14-08: Avid is CMO for Arius Research's lead drug, "AR001 Targeting CD44": - 7-23-08 Roche buys Arius for $190mm

...Excellent Exosome (aka microparticles, microvesicles) info:
9-11-17/Status: "The company continues to make progress... The assay has been successfully optimized; we are evaluating options to license/partner/sell this technology."
6-22-17: Nature/BJoC, Dr. Alan Schroit/UTSW etal: "Detection of PS+ Exosomes for the Diagnosis of Early-Stage Breast & Pancreatic [Betabody KL15C]"

2-9-17/PR: PS+ Exosomes Proof-of-Concept Data (N=44, Ovarian, Dr. Alan Schroit/UTSW etal) pub. 1-22-17 in OncoTarget
...Data (blinded plasma from 34 O.C. pts & 10 healthy subjects) supports the “high diagnostic power” of PS+ Exosomes in Ovarian Malignancies.
...Dr. Stephen Worsley (VP/BusDev): “...we believe this has potential app's in several solid tumors beyond ovarian cancer. With that in mind, we look forward to aligning with a partner to help explore the potential of this promising technology."
...PPHM’s PS Exosomes platform advantages outlined: UTSW/website and World Patent #WO/2016/201064:
......U.S. Patent app. #20170146542 “DIAGNOSTIC TEST FOR EARLY STAGE CANCER” pub. 5-25-17 (A.Schroit, S.Ward, A.Gazdar)
7-14-16: Peregrine Licenses Exosome-based technology from UTSW (Inventors: Alan Schroit/Philip Thorpe)
...“relates to assays that are able to detect small amts of PS+ Exosomes in a patient's blood sample as a way to detect cancer at a very early stage of development.”
...Dr. Jeff Hutchins (VP/PreclinRES): "Once we have successfully validated this assay, we plan to establish proof-of-concept through an efficient preclinical & clinical testing pgm. We have no intention of conducting further development work beyond the proof-of-concept stage. Rather, we expect to initiate partnering discussions for commercialization of this pgm in 2017.

3 NCCN Bavituximab Trials Announced 9-6-16 ($2mm grant from PPHM)
#1: Ph1/HepC-Related Hepatocellular(Liver) (Bavi+RAD+Bayer’s Nexavar=Sorafenib), MOFFITT CC (N=18)
. . . . . . .PI: Jessica Frakes, MD <=Recruiting a/o 3-27-17
#2: Ph2/Newly Diag. Glioblastoma (Bavi+RAD+Merck’s Temodar), MASS-GEN. & DANA FARBER (N=36)
. . . . . . .PI: Elizabeth Gerstner, MD <=Recruiting/6-16-17; 1stDose/9-7-17
#3: Ph2/Progressive Squamous Head+Neck (Bavi+Merck’s Keytruda), JOHNS-HOPKINS(Sidney Kimmel CC)
. . . . . . .PI: Ranee Mehra, MD - See Dr. R.Mehra Jan'17/IFN-y Biomarker:

A. Phase III Bavi+Doce vs. 2nd-Line NSCLC "SUNRISE" (randomized, double-blind, placebo-ctl'd, n=582)
USA Protocol: <=chgd. to "Active, Not Recruiting." 2-1-16
...2 ARMS: A=BAVI/3mg+DOCE(Weekly), B=Doce+Placebo(Weekly)
...ECOG's: Ph3SUNRISE/0-1, Ph2Bavi+Doce(n=120)/0-1-2, Ph2Bavi+Durva(AZN)/0-1, Ph3Herbst2010/0-1 (2L/NSCLC)
...161 sites a/o 7-9-15 (USA/39 Aus/9 Bel/7 Fr/9 Ger/15 Greece/10 Hungary/7 Italy/10 Korea/9 Rom/6 Rus/8 Spain/16 Taiwan/10 Ukraine/6) - Growth:
...Sunrise Biomarker studies - 4 announced thru ASCO'17, see
......#1 10-10-16/ESMO’16: B2GPI/200-240(30%pts) StatSig MOS 7.7=>13.2mos.
......#2 12-7-16/WCLC’16(IASLC): “Complement & IL-10 Pathways: Pts Benefiting from Bavi+Doce” <=Presentation CANCELLED/”Anal.Not.Finished(IR)”
......#3 4-3-17/AACR'17: "IFN-y Analysis In Blood & Tissue as a Potential Prognostic and/or Predictive Biomarker” See:
......#4 6-3-17/ASCO'17: "Prelim. Correlative Analysis of PD-L1 Expression from the Sunrise Study” See ASCO'17:
10-17-17/WCLC’17(IASLC): SUNRISE Subset Data (n=93) ”N=46 rec. ICI after Bavi/MOS not yet reached v. n=47 didn’t rec. Bavi/MOS=12.6mos.”
9-9-17/ESMO’17(Madrid): Final SUNRISE Ph3 Data to be presented (poster# 1364P)
..."In an exploratory analysis of OS for pts who received subsequent immune checkpoint inhibitors (ICI), mOS was not reached.”
2-25-16: IDMC Halts SUNRISE at 1st Look-in. Bavi+Doce arm “OS performing as expected”; Doce arm “dramatically outperforming OS expectations”
...CC Replay: 12:22/Q&A: RahulJasuja/Noble, “You said that the performance of the Doce/Ctl arm was higher than ever seen in such a trial?” - SK “Yes, we've never seen these #'s reported. It's quite perplexing… at this point, the performance of the Doce arm was just completely out in left field.”
2-1-16: SUNRISE Trial status updated: “Study ongoing, but not recruiting.”
12-10-15: “Sunrise >90% enrolled; sufficient to allow the 2 planned interim looks (33%/50%) & final readout based on PrimEndPt=OS”
5-31-14 ASCO’14: David Gerber/Joe Shan Poster on Ph3/SUNRISE Trial (#TPS8129)
3-7-14: PR & Conf-Call: "first patients enrolled and dosed."
1-6-14: FDA grants FAST TRACK status to Bavi in 2ndLine NSCLC
12-30-13: Pivotal Ph.3 ‘SUNRISE’ NSCLC Trial Initiated (n=~600, sites=100+)
5-20-13: FDA Approves Bavituximab Ph.III Design for 2L/NSCLC; 600-pt trial to begin by y/e’13
...S.King: “We will now focus on starting the Ph.III trial while continuing ongoing partnering discussions.”
…R.Garnick: “This was a highly collaborative effort with the FDA; this trial, when combined with Bavi’s supporting data to date, could be sufficient to support a future BLA submission."

These 2nd 10 (latest ones, 2010-2015) completed Ph.1/2 Bavi Trials archived to:
O. 6th IST Trial: Bavi+Ipilimumab(Yervoy) vs. Adv.Melanoma (Ph1b, random, open-lab, 2arms, n=24)
N. 5th IST Trial (Bavi+Capecitabine+RAD) vs. Rectal Cancer (Ph1, open-lab, 1arm, n=18)
M. Tumor Imaging/Dosimetry trial of I124-PGN650 (FH-Bavi) in Adv. Solid Tumors (Ph0, open-lab, 1arm, n=12)
L. 4th IST Trial (Bavi+Cabazitaxel vs. PROSTATE, open-lab Ph.1B/IIA) CANCELLED/SOC-Chg.
K. 3rd IST Trial (Bavi+PemCarbo vs. Frontline NSCLC, open-lab Ph.1B, n=25)
J. 2nd IST Trial (Bavi+Paclitaxel(Taxol) vs. Her2- Met. Breast Cancer, open-lab Ph.1, n=14)
I. Ph.II Bavi+GEM vs. Front-Line Adv. PANCREATIC (randomized, unblinded, n=70)
H. 1st IST Ph.I/II Trial (Bavi+Sorafenib vs. Liver, open-lab, n=9+38=47)
G. Ph.IIb Bavi+PC vs. Front-Line NSCLC (randomized, unblinded, 'confirmatory', n=86)
F. LEAD IND: Phase IIb Bavi+Doce vs. 2nd-Line NSCLC (random/double-blind, n=120, 'registrational')
These 1st 5 (oldest ones, 2005-2009) completed Ph.1/2 Bavi Trials archived to:
1. Ph.1A Bavi/Mono vs. Solid Cancers (USA n=26, 6/2005-6/2009)
2. Ph.1B Bavi+Chemo vs. Solid Cancers (India n=12, 11/2006-5/2007)
3. Ph.2 Bavi+Doce/BREAST/Refractory (RepGA n=46, 1/2008-5/2009): ORR=61%(Her2+=86%), MOS=20.7mos
4. Ph.2 Bavi+PC/BREAST/Frontline (India n=46, 8/2008-9/2009): ORR=74%(Her2+=100%), MOS=23.2mos
5. Ph.2 Bavi+PC/NSCLC/Frontline (India n=49, 6/2008-10/2009): ORR=43%, PFS=6.1mos, MOS=12.4mos

1-18-18: Peregrine's 2017 ASM (Avid/Myford, Tustin) ...PROXY/14A iss. 12-7-17:
12-11-17: Qtly. Conf. Call (Lias/Lytle/???) Transcript

...Dr. Lias, "the company is undergoing a broad-scale transformation, the goals of which are to shift complete focus to the Avid Bioservices CDMO business and the complete divestiture of all of Peregrine's legacy R&D assets, which include bavituximab."
11-28-17: PPHM+RONIN Settle - Reconstituted 7-Member BOD (Johnson/Swartz/Pohl/King resign)
...Full Agreement(8-K): Header: Complete Agreement:
...Profiles of all 7 BOD members & Compensation as of 11-28-17:
.....(Joseph Carleone/Chair, Richard Hancock, Gregory Sargen, Joel McComb, Roger Lias, Mark Bamforth, Patrick Walsh)

Sept-Nov2017 PPHM/Form4’s for reconstituted 7-person BOD (Options Awarded):
...Joseph Carleone (Chairman): 75,000 @4.67, vesting monthly over 3yrs beg. 12-27-17
...Richard Hancock: 75,000 @4.67 vesting monthly over 3yrs beg. 12-27-17
...Gregory Sargen: 75,000 @4.67, vesting monthly over 3yrs beg. 12-27-17
...Joel McComb: 75,000 @4.67, vesting monthly over 3yrs beg. 12-27-17
...Patrick Walsh: 75,000 @4.08, vesting monthly over 3yrs beg. 11-20-17
...Mark Bamforth: 75,000 @3.88, vesting monthly over 3yrs beg. 11-17-17
...Roger Lias: 150,000 @3.19, vesting in 4 equal annual installments beg. 9-25-18
...OPEN MKT PUR: Mark Bamforth Buys 50,000sh. @$4.50 (open mkt) on 10-27-17

11-15-17/Outsourcing-Pharma: “How This R&D Company (Peregrine) is Transitioning to a Pure-Play CDMO: ‘Opportunities Are Almost Endless’" - Recap of interviews with Steve King & Avid Pres. Roger Lias
11-13-17/PR: Peregrine's 2017 ASM to be held 1/18/18 at Avid (VotingRecDate=11-27-17):
10-23-17/8-K: “Recently Amended” BOD Compensation Pgm  $55000/yr + $15000/committee + $2000/meeting
10-24-17: Peregrine Adds Patrick D. Walsh to BOD, "An Industry Veteran with 30+yrs Experience Leading Successful CDMO Org’s”
10-19-17: Peregrine Adds Mark R. Bamforth to BOD, "10yrs/Genzyme; 30yrs of biologics leadership experience, incl. founding 2 CDMOs"
...10-27-17/Form4: Mark Bamforth buys 50,000sh. @$4.50 (open mkt):
9-11-17: Roger J. Lias (ex-Allergan) to become Avid’s President and join PPHM’s BOD eff. 9-25-17
9-11-17: Qtly. Conf. Call (King/Lias/Lytle) Transcript
...CEO SK: “For this reason, we have concluded that in order to best position Peregrine’s R&D assets for successful development, they should be advanced by a partner with the appropriate expertise and ample resources to invest in the necessary clinical trials. To that end, we have been working diligently towards the transformation of the overall business to becoming a pure-play CDMO, while assessing the best strategic options for the R&D assets that would allow stockholders to directly see the future value from their continued developments. By partnering & eliminating future R&D expenditures, we believe we are best positioning Avid for future growth. Through reinvestment & expansion, we believe we will attract new customers and extend current contracts that will help position Avid as a leading U.S. CDMO. We are moving forward expeditiously with strategic discussions as we recognize the need to move quickly both from the R&D & CDMO standpoints. We hope to bring this process to completion over the coming months and will update you on our progress.”
7-14-17: Qtly. Conf. Call (King/Shan/Lytle) Transcript
...CEO SK: “We are seriously considering the possibility of separating our 2 distinct businesses, Avid and R&D/PS-Targeting.”
3-13-17: Qtly. Conf. Call (King/Shan/Worsley/Lytle) Transcript
...CEO SK: “We believe the recent improvement of stock price is a growing recognition of the value of Avid, and having the full value of the Avid business reflected in our stock price is a top priority.”
12-12-16: Qtly. Conf. Call (King/Shan/Hutchins/Lytle) Transcript
...CEO SK: “Our goal is to bring the overall company to profitability within the next 18mos. We believe just the value of Avid Bioservices is far greater than our current market cap and is only growing in value."
10-13-16 Peregrine's ASM: ATTENDEE Reports & Link to CEO Steve King's 35min/45slide webcast:
9-8-16: Qtly. Conf. Call (King/Shan/Garnick/Hutchins/Lytle) Transcript
...CEO SK: “Our ultimate goal remains to reach overall profitability within the next 21mos, and Avid will be an important driver for achieving that goal, in combination with making strategic investments in our R&D while pursuing partnerships to help advance our programs.”
7-14-16: Qtly. Conf. Call (King/Garnick/Hutchins/Shan/Lytle) Transcript (Avid revs guidance for FY17=$50-55mm, curr. committed B/L=$68mm)
...CEO SK: “The recent licensing of Novel PS Exosome Tech. for detection/monitoring of cancer from UTSW will allow the co. to continue its R&D activities with significant upside coming from partnering as we move towards profitability.”
6-2-16: Corp.Update – Avid Expansion & Drug Development -
...Avid Revs for FY16(fye 4-30-16) will be $44mm; B/L=$56M; FY17/guidance=$50-55mm(3 curr. clients). Avid III being designed/already secured 25,000sf loc/expect complete=1H/2017. “Expect future sustainable profitability for the company in 24mos.”
3-9-16: Qtly. Conf. Call (King/Shan/Worsley/Lytle) Transcript
...CEO SK: “Peregrine remains a strong company with a valuable clinical asset and a rapidly growing biomfg. business... We believe our relationships with AstraZeneca, Mem. Sloan Kettering, UTSW, & NCCN will be invaluable as we establish & execute our overall strategy for advancing the bavituximab I-O combination plans in a range of cancers.”
3-7-16: Formal Commissioning of Avid's New 40,000sq "Myford" Facility, “single-use/fully disposable” (potentially $40M addl revs)
2-25-16: IDMC Halts Ph.3/NSCLC SUNRISE Trial at 1st Look-in. Bavi+Doce arm “OS performing as expected”; Doce arm “dramatically outperforming OS expectations”
1-18-16: CEO Steve King's 1-18-16 presentation at Noble-Financial's Investor Conf. (21min replay, 31 slides)
1-11-16: Update on 4 New Bavi Clinical Trials (Lung/AZN, Breast/1Co./1MSKCC, Other Cancers/AZN). SUNRISE est's: Look1=Early'16, Look2=Mid'16, FinalUnblind=End'16
1-6-16: Peregrine enters into Research Collab. with Natl-Comprehensive-Cancer-Network (NCCN)
...$2mm res. grant to NCCN's Oncology Res. Pgm (ORP), will “significantly expand our clinical evaluation of Bavi and augment Peregrine's IST pgm at 26 of the world's leading cancer centers”.
12-10-15 Qtly. Conf. Call (King/Shan/Worsley/Garnick/Lytle) Transcript
...CEO SK: “Although our SUNRISE enrollment milestone has been reached, we have no intention of slowing down, quite the opposite. We are aggressively moving to initiate new clinical trials [Lung, Breast, Mult-Types] that will allow us to build the most robust oncology business possible… With each of these studies our goal is the same - we are committed to identifying key indications, patient populations, and therapeutics that can benefit from combination treatment with bavituximab. From what we have seen to-date, the opportunity appears vast and we are hard at work converting the most promising prospects into true value.”
10-15-15 Peregrine's ASM: ATTENDEE Reports & Link to SK's 18min/16slide webcast:
10-15-15: Peregrine & AstraZeneca Expand Collab. w/Ph2/2ndLine-NSCLC Trial, Bavi+Imfinzi(durvalumab), squamous or non-squamous.
9-9-15: Qtly. Conf. Call (King/Shan/Worsley/Lytle) Transcript
...CEO S.King: “The Memorial Sloan Kettering & AstraZeneca collaborations are an important part of our announced plans to expand our bavituximab clinical pgm.”
8-24-15: AstraZeneca & Peregrine Collaborate on Bavi+Imfinzi(durvalumab) Ph1/1B Trial for “multiple solid tumors”
...Imfinzi=durvalumab=MEDI4736(anti-PD-L1 immune checkpoint inhibitor). AZN’s Head/I-O(Robert Iannone): “Our partnership with Peregrine provides the opportunity to explore an exciting, novel combination that could deliver important clinical benefit to patients across a range of cancers."
7-14-15: Qtly. Conf. Call (King/Shan/Hutchins/Lytle) Transcript
...CEO S.King: “We recently entered into collaboration with investigators at Memorial Sloan Kettering Cancer Ctr to continue expanding on this important work, as well as to explore other potential applications of bavituximab and other agents that target PS-signaling pathway.”
5-29-15: Peregrine & Sloan Kettering Enter Collab. to “Investigate Novel PS-Targeting Immunotherapy Combos”
3-12-15: Qtly. Conf. Call (King/Garnick/Shan/Hutchins/Lytle) Transcript   
...CEO S.King: “Bavituximab represents the most clinically advanced agents that target the immunosuppressive PS signaling pathway, and we are driven to bring this product to the market and believe it has the potential to help change the way cancer patients are treated. Our Ph.3 SUNRISE NSCLC trial continues to make great progress & is on track to complete enrollment in the study by YrEnd’15.”
3-9-15: CEO Steve King’s 24min. talk at ROTH Conf. (DanaPT CA) - SLIDES 
12-10-14: Qtly. Conf. Call (King/Shan/Hutchins/Lytle) Transcript
...CEO S.King: “We believe Peregrine is in a unique position with an immune-oncology program already in Phase III, with what has been a positive safety profile and a target that is ideal for combining with other IO agents.”
10-16-14 Peregrine's ASM: Slides(42), Audio-Replay-Link, Attendee-Reports
9-9-14: Qtly. Conf. Call (King/Hutchins/Shan/Lytle) Transcript
...CEO S.King: “In addition to our clinical trials, many of which have also have translational data points built in to tie together pre-clin. data with the clinic, we have also continued to build momentum in our pre-clin. collaborations which now number in the dozens. We are evaluating new combinations & dosing strategies combining bavituximab with chemotherapy, radiation, and immune-oncology approaches, including those targeting CTLA-4, PD-1, as well as other downstream immune checkpoints."
7-14-14: Qtly. Conf. Call (King/Shan/Hutchins/Worsley/Lytle) Transcript
...CEO S.King: “Partnering remains a priority with the goal being to use partnerships to continue expanding the bavituximab program, while we continue to execute the SUNRISE Phase III trial.” 
3-10-14: CEO Steve King’s 22min. talk at ROTH Conf. (DanaPT CA) - SLIDES
3-7-14: Qtly. Conf. Call (King/Shan/Garnick/Lytle) Transcript
...CEO S.King: “I don't want to overuse the word ‘excitement’, but these are truly exciting times that have positioned us for success on all fronts.” 
12-10-13: Qtly. Conf. Call (King/Shan/Garnick/Hutchins/Worsley/Lytle) Transcript
...With recent scientific insights highlighting bavi’s immunostimulatory moa, these additions to PPHM’s SAB: Dimitry Gabrilovich, Scott Antonia, David Carbone, Hakan Mellstedt
...CEO S.King: “We believe that Peregrine is uniquely positioned among the companies developing immunotherapies… and that because of our current valuation, we represent a unique investment opportunity.” 
11-2013: Stephen Worsley joins Peregrine as VP of Bus.Dev. 
11-12-13: CEO Steve King's 23min. talk at Credit-Suisse Conf. (Scottsdale) 
9-9-13 Qtly. Conf. Call (King/Hutchins/Shan/Lytle) Transcript
...CEO S.King: “In addition to the immunotherapy research, there has been significant interest in the results presented at ASCO showing an 84% tumor response rate in HER2- breast cancer patients.”
8-14-13: CEO Steve King's 26min. talk at Wedbush/NYC - SK. "We have very active partnering discussions [ongoing] around our 2 lead programs.”
7-11-13: Qtly. Conf. Call (King/Shan/Garnick/Lytle) Transcript
...CEO S.King: “This [new bavi] moa insight has opened the door to completely new combinations not previously explored.  Bavi acts on an upstream immune checkpoint, and thus, makes a potentially ideal combination with downstream-acting immune checkpoint inhibitors such as anti PD1 antibodies & CTLA-4 targeted approaches…  Preclinical studies are well underway to explore these combinations, and we look forward to generating and reporting data later this year that could support moving these concepts into the clinic.”
6-27-13: Updates on Bavituximab Pgm. & Cash Position
…“primary focus remains on the init. of the PhIII trial in 2nd-Line NSCLC by y/e; recent data supporting an immunotherapy moa for bavituximab opens many new development opportunities including new combinations not previously planned and has created a lot of excitement around the potential of bavituximab in combination with other immunotherapeutic agents…"
4-2-13: Peregrine Mourns Loss of Dr. Philip E. Thorpe (1951-2013)  
3-18-13: CEO Steve King's 27min. talk at Roth Conf.(DanaPT CA) - Excerpts & SLIDES  
…CEO S.King: "Our goal is to initiate the Phase III trial (2ndLine NSCLC) by the end of 2013."
3-12-13: Qtly. Conf. Call (King/Shan/Garnick/Lytle) Transcript   
...Rob Garnick (Head/Reg.): "Re: 2nd-Line NSCLC: …the 3rd piece, which is important, is the efficacy piece, and as I point out to many people, there are very few and far between Phase II trials that ever show statistical significance in efficacy - that's an absolutely unbelievable hurdle for a Phase II product.  And, what you're really looking for is an ability to describe that you do have clinical efficacy, and as Joe has said, showing 11.7 mos. for the 3mg arm and a difference in the pooled dataset for the product of 7.3 mos. when you combine the control & the placebo, definitely gives you the indication that in overall survival, we have a potentially highly efficacious product… we're going to discuss the entire situation of the investigation with the agency, as well as all the data I just described, and we feel pretty confident that we have enough data to move the product effectively into Phase III."
3-5-13: CEO Steve King's 24min. talk at Cowen HC Conf.(Boston) - Excepts & SLIDES

ARTICLES, ANNUAL SHM'S, & CC'S - Archive 2010-2012:
ARTICLES, ANNUAL SHM'S, & CC'S - Archive 2005-2009:

BAVITUXIMAB ANTI-CANCER NEWS (see above for Trials Info):
4-4-17: AACR'17: 5 posters, incl. new 2nd MSKCC/Wolchok Bavi+ACT study -
4-20-16 AACR'16 & 4-4-16/Cancer-Immunology-Res.(AACR) article - preclin. data: Bavi combo w/anti-PD-1/anti-CTLA-4 “induces a shift in tumor microenvironment from immunosuppressive to immune active”
6-1-15 ASCO’15: 3 Bavi/AntiPS Posters (NSCLC, Melanoma, Breast, Liver) & Plans to add Ph2/3 Bavi Trials (NSCLC/Optivo, Her2- Breast)
4-20-15 AACR’15: 3 Abstracts/2 PR’s - Bavi Clinical TransData/Lung & PreClinData/Melanoma/Breast – Moffitt/S.Antonia, UTSW/R.Brekken, UC-Irvine/CW.Hughes, Peregrine
4-2014 AACR'14: Peregrine's 3 preclin. posters 
...about Bavi as an “Upstream PS Checkpoint Inhibitor”; notably, “when combined with downstream immune checkpoint inhibitors such as anti-CTLA-4 and anti-PD-1, PS targeting mediates an improved protective tumor-specific immunity following tumor rechallenge”, and, “combination of bavituximab with the anti-PD-1 checkpoint blockade should synergistically induce potent long-lasting antitumor immunity.”
4-2013 AACR'13: Peregrine's 3 preclin. posters
..."data on the immune stimulating moa of Bavi, anti-tumor & imaging potential of other PS-targeting constructs"

10-2017/Mol-Imag: Results of Human Testing (n=11) of 124I-PGN650 PET Imaging
...”Tumor targeting in Pts was less than prev. observed in animal studies… tumor uptake was quite low & not sufficient for clinical studies.”
5-25-16/OncoTarget, “PS-Targeted Liposome [PGN635=Fhu-Bavi] For Enhanced Glioma-Selective Imaging” - Wake Forest's Dawen Zhao & UTSW's Liang Zhang
6-2014: Two Bavi-Imaging abstracts by UTSW at Society of Nuclear Med+Molecular Imaging (SNMMI) Annual Mtg
11-26-13: PGN635 (Fhu-Bavi) Imaging article in Molecules2013 by UTSW’s Liang Zhang & Dawen Zhao
12-19-13/PLOS/Philip Thorpe: “Highly Specific PET Imaging of Prostate Tumors in Mice with an Iodine-124-Labeled Antibody Fragment That Targets PS”
ANTI-PS IMAGING - Archive 2006-2012:

11-1-15-UTSW/Mayo/Tulane/PRC: “PS-Targeting Mabs Inhibit Choroidal Angiogenesis InVivo & ExVivo” [CNV/Macular Degen]
5-2012: Two Anti-PS (PGN632 + PGN635) Ocular posters at ARVO'12 Annual Mtg./FtLaud
..5-6-12/Thorpe+Mayo, "Anti-PS (PGN632 & PGN635) as Potential New Therapy Against Choroidal Neovascularization (CNV) - AMD"
..5-10-12/PPHM+LSU, "Efficacious Clinical Outcome of an Ophthalmic Formulation of PS-binding mab (PGN632) in a Rabbit Model of Acute HSV-1 Keratitis"

These 4 completed Ph.1/2 Bavi HCV Trials archived to:
4. Phase II Bavi+Riba vs. Frontline-HEPC (randomized, open-label - 2011)
3. Phase 1B HCV-HIV Co-Infected's Mono Repeat-Dose Trial (2007-2011)
2. Phase 1B Bavi/Mono Repeat-Dose HCV Trial: (init=6-2006 comp=1-2007 n=24)
1. Phase 1A Bavi/Mono Single-Dose HCV Trial: (init=8-2005 comp=2-2006 n=30)

...Also see 3-2012 Earlier Archive of 2008-2011 DTRA Gov't Contract:
...Also see 3-2012 Earlier Archive of Duke-PPHM-Chavi-Cavd HIV Collaboration:
...Also see 3-2012 Earlier Archive of Other Anti-Viral News (2005-2008):

This defunct 1998-2012 pgm. archived to:

AFFITECH-PPHM Collab: Fully-Human Mabs, Anti-PS & Anti-VEGF/2C3
This defunct 2005-2012 pgm. archived to:

Dr. Phillip Thorpe Discusses BAVITUXIMAB at 2004 ASM (Bavi was formerly brand-named "Tarvacin"):
10-25-04 SHM Presentation: "Understanding Tarvacin", incl. his first-ever public comments about Tarvacin's ANTI-VIRAL capabilities:
"OK, this is Tarvacin.. the cleanest tumor vessel marker of which we are aware.. If you look here at the 3G4 slide, you'll see, most remarkably, that it's absolutely chock full with macrophages; they're beginning to outnumber the tumor cells... . So, the conclusions with Tarvacin are that it has a unique mechanism of action, there's nothing else like it out there; it homes specifically to tumor blood vessels and induces white blood cells to attack the tumor."

Dr. Thorpe's APT (AntiPS/3G4/BAVITUXIMAB patent app #20040161429 (pub. USPO 8-19-04):
"Compositions for treating Viral Infections using Immunoconjugates to Aminophospholipids":
[1302] "the 3G4 antibody has enormous potential as a broad spectrum anti-viral agent."
[1303] "...The inhibitory activities of 3G4 on cell division, angiogenesis, tumor growth & viral infectivity, taken together with lack of apparent toxicity, show broad therapeutic indications for this antibody, including in the treatment of angiogenic disorders, cancer, diabetes and viral infections."
[0196] "the anti-viral methods and uses of the invention are suitable for treating all viruses... as exemplified by treating CMV, RSV, arenavirus and HIV infections, and the diseases hepatitis, influenza, pneumonia, Lassa fever and AIDS."
[1298] "The 3G4 antibody has also been administered to monkeys in safety studies and no side effects have been observed."

The Inventor of the PS-Targeting Mabs, like 3G4/bavituximab, is Dr. Philip E. Thorpe of UTSW-MC/Dallas.
4-2-13: Peregrine Mourns Loss of Dr. Philip E. Thorpe (1951-2013)
…2013: Dr. Thorpe’s lab taken over by UTSW’s Dr. Rolf A. Brekken:
Dr. Thorpe's Patents: GRANTED: PENDING:
…Dr. Thorpe's Articles: Also see:
Dr. Brekken’s Patents: GRANTED: PENDING:
…Dr. Brekken’s Articles: Also see:
Dr. Alan Schroit's Patents (MDA/UTSW, PPHM SAB, “Clipped B2GP1”, PS-Exosomes): GRANTED: PENDING:
…Dr. Schroit’s Articles: Also see: (UTSW profile)

PPHM BOARD RULES:  - DISCLAIMER: This msg board is not affiliated with Peregrine; no endorsement by Peregrine or any other org. is implied.

Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PPHM News: Peregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2018 and Recent Developments 12/11/2017 04:05:00 PM
PPHM News: Peregrine Pharmaceuticals Declares Quarterly Dividend on its Series E Convertible Preferred Stock 12/07/2017 04:05:00 PM
PPHM News: Peregrine Pharmaceuticals to Report Financial Results for Second Quarter of Fiscal Year 2018 After Market Close on December 1... 12/04/2017 04:05:00 PM
PPHM News: Avid Bioservices Announces Appointment of Tracy Kinjerski as Vice President of Business Operations 11/29/2017 08:05:00 AM
PPHM News: Peregrine Pharmaceuticals, Ronin Trading and SW Investment Management Announce Settlement Agreement 11/28/2017 08:05:00 AM
#320583  Sticky Note 12-11-17 Qtly CC-Transcript, PR(Fin’s Q2FY18/qe10-31-17), Avid Revs History Table cjgaddy 12/12/17 02:32:53 PM
#320228  Sticky Note 12-7-17/PROXY; 11-28-17 PPHM+RONIN Settle(4 New Directors) cjgaddy 12/07/17 06:37:13 PM
#319736  Sticky Note 11-28-17: Profiles of All 7 BOD Members (+Compensation) cjgaddy 11/30/17 08:48:38 AM
#303699  Sticky Note 7-14-17: Updates on the PS Exosomes Diagnostic Platform cjgaddy 07/15/17 04:27:09 PM
#298792  Sticky Note Sunrise Biomarkers (#1/B2GPI #2/COMPL,IL10 #3/IFN-y #4/PD-L1) – updated cjgaddy 06/06/17 12:10:40 PM
#294957  Sticky Note PPHM/MSKCC(Jedd Wolchok Lab) Collab: #1/Bavi+PD1+Rad, #2/Bavi+”ACT” cjgaddy 04/14/17 10:05:54 AM
#320787   I GUESS : 249999999,1239 + A PEANUT Mauriziomh 12/15/17 02:25:11 AM
#320786   Guess the amount you think the Peregrine IP vinmantoo 12/15/17 02:16:36 AM
#320785   I'm sure that I will get blasted by horselover45 12/14/17 11:22:53 PM
#320784   And wait til they come back for a geocappy1 12/14/17 11:13:45 PM
#320783   And keep in mind, we are now getting The Other Guy 12/14/17 11:08:20 PM
#320782   This has nothing to do with PPHM TampaTradr 12/14/17 10:47:36 PM
#320781   Exactly...this pos done ....the crooks get to Bluerinse 12/14/17 10:39:16 PM
#320780   March 28, 2018 biopharm 12/14/17 10:36:15 PM
#320778   That would be quite a one time dividend biopharm 12/14/17 09:50:25 PM
#320777   20,000,000+milestones. BTW, anyone can explain how will the 600M EndoTarget 12/14/17 09:42:08 PM
#320776   Maybe you are forgetting how much time is EndoTarget 12/14/17 09:28:07 PM
#320775   Would appear he will be the public voice revenue_monster 12/14/17 09:08:34 PM
#320774   Could it be that the previous BOD were war0001 12/14/17 08:54:01 PM
#320773   Called that one......... patientlywaiting 12/14/17 07:55:47 PM
#320772   hayward, tomorrow is the 3rd day. It took CloakedProtector 12/14/17 07:31:21 PM
#320771   And the Beat goes on. JamesGMS 12/14/17 06:36:01 PM
#320770   And the state of Kentuckiana casts all 7400 TekNuLoof 12/14/17 06:29:34 PM
#320769   That was fast. exwannabe 12/14/17 06:08:17 PM
#320768   Lias is new ceo?... On December 10, r622102675 12/14/17 05:37:10 PM
#320767   Put that article in a letter to the north40000 12/14/17 04:24:17 PM
#320766   wow. way too much. will revenue_monster 12/14/17 04:12:54 PM
#320765   Interesting read . . . epcjmc 12/14/17 03:12:59 PM
#320764   "See you at the ASM!" patientlywaiting 12/14/17 03:09:39 PM
#320762   CloakedProtector You also said we would be back to hayward 12/14/17 02:45:24 PM
#320761   djohn, the fat lady ain't sung yet. shipbuilder 12/14/17 02:17:51 PM
#320760   These results support further investigation of these markers djohn 12/14/17 02:04:47 PM
#320759   it will be a small miracle if we ElSid18 12/14/17 02:04:10 PM
#320758   CAR-T cells and combination therapies: What's next in hutschi 12/14/17 02:01:11 PM
#320757   This is just like the old days! Everyone djohn 12/14/17 01:58:42 PM
#320756   1.59. The price of Small progresso Italian Breadcrumbs. Along4theRide 12/14/17 01:56:47 PM
#320755   PPHM Anonymous is the genisis wrung on a shipbuilder 12/14/17 01:41:26 PM
#320754   This message board has feel/sound of an AA drontle2 12/14/17 01:30:32 PM
#320753   Recall biomarker # 3, presented at AACR 2017. north40000 12/14/17 01:12:53 PM
#320752   $69 shipbuilder 12/14/17 12:42:28 PM
#320751   Ok, I'm all filled. Now we can bidrite 12/14/17 12:17:53 PM
#320750   Wouldn't surprise me if we finish @ $4.50 r622102675 12/14/17 12:16:19 PM
#320749   bidrite, then it is not the MM but CloakedProtector 12/14/17 12:04:40 PM
#320748   I believe that to be a true statement JC! bidrite 12/14/17 12:04:11 PM
#320747   I say we close green today just JCNJ 12/14/17 11:56:52 AM
#320746   The order is getting filled 100 shares at bidrite 12/14/17 11:55:00 AM
#320745   bidrite, unless you have specified options with your CloakedProtector 12/14/17 11:53:00 AM
#320744   Just FYI - that bid at $4.11 that bidrite 12/14/17 11:44:28 AM
#320743   Wow, very in-depth and glad to see the bidrite 12/14/17 11:19:00 AM
#320742   north, two things (KITE, JUNO, NOVARTIS and PPHM). CloakedProtector 12/14/17 11:16:47 AM
#320741   Every research article regarding PS says " but asmarterwookie 12/14/17 10:39:29 AM
#320740   James CMS, thanks. Looks like some pros swg_tdr 12/14/17 10:28:48 AM
#320739   If that is the case and I hope Threes 12/14/17 10:24:47 AM
#320738   Think from another angle.....Ronin Capital Management "group" possibly biopharm 12/14/17 10:18:58 AM
#320737   If it is the key to unlocking the ku 12/14/17 10:13:07 AM
#320736   I am not very optimistic. Why don't you geocappy1 12/14/17 10:09:33 AM